2. Academic Validation
  3. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment

The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment

  • Int J Mol Sci. 2021 Oct 3;22(19):10719. doi: 10.3390/ijms221910719.
Nadia Bolandi 1 2,  Afshin Derakhshani 1 3,  Nima Hemmat 1,  Amir Baghbanzadeh 1,  Zahra Asadzadeh 1,  Mina Afrashteh Nour 1 2,  Oronzo Brunetti 4,  Renato Bernardini 5,  Nicola Silvestris 4 6,  Behzad Baradaran 1 7 8
Affiliations

Affiliations

  • 1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 516615731, Iran.
  • 2 Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia 571478334, Iran.
  • 3 Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy.
  • 4 Medical Oncology Unit-IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy.
  • 5 Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95100 Catania, Italy.
  • 6 Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari, 70124 Bari, Italy.
  • 7 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 516615731, Iran.
  • 8 Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz 516615731, Iran.
PMID: 34639059 DOI: 10.3390/ijms221910719
Abstract

Gastric Cancer (GC), with a heterogeneous nature, is the third leading cause of death worldwide. Over the past few decades, stable reductions in the incidence of GC have been observed. However, due to the poor response to common treatments and late diagnosis, this Cancer is still considered one of the lethal cancers. Emerging methods such as immunotherapy with immune checkpoint inhibitors (ICIs) have transformed the landscape of treatment for GC patients. There are presently eleven known members of the B7 family as immune checkpoint molecules: B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), B7-DC (PDCD1LG2, PD-L2, CD273), B7-H2 (B7RP1, ICOS-L, CD275), B7-H3 (CD276), B7-H4 (B7x, B7S1, Vtcn1), B7-H5 (VISTA, Gi24, DD1α, Dies1 SISP1), B7-H6 (NCR3LG1), B7-H7 (HHLA2), and Ig-like domain-containing receptor 2 (ILDR2). Interaction of the B7 family of immune-regulatory ligands with the corresponding receptors resulted in the induction and inhibition of T cell responses by sending co-stimulatory and co-inhibitory signals, respectively. Manipulation of the signals provided by the B7 family has significant potential in the management of GC.

Keywords

B7 family; gastric cancer; immune checkpoints; immunotherapy.

Figures
Products